AcelRx Pharma (ACRX): Emergency Physician Survey Bodes Well For ARX-04 - Jefferies

October 4, 2016 7:28 AM EDT
Get Alerts ACRX Hot Sheet
Price: $3.20 --0%

Rating Summary:
    6 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 6 | New: 4
Trade ACRX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst, Hugo Ong, reiterated his Buy rating for AcelRx Pharmaceuticals (NASDAQ: ACRX), after conducting a proprietary Emergency Dept physician survey on trends for acute pain in the ED to gauge the outlook for ARX-04, which could be available by YE'17. Physicians had a bright outlook citing expected ARX-04 use on par with IV morphine for moderate pain (~19%), and exceeded it in severe pain (~27%) for '18. The analyst believes the results bode well for ARX-04 in 2018.

The majority of ED physicians see ARX-04 as appropriate in a variety of situations. The anlayst asked respondents what situations were most appropriate for ARX-04, and presented them with a variety of injuries/conditions. The top conditions included: physical trauma (i.e. bone fractures, etc.; ~76%), 2nd/3rd-degree burns (~84%), sickle-cell crisis (~88%), endstage cancer pain (~96%), and kidney stones (~76%). Nearly all (~96%) physicians believed that the ED following evaluation or during a procedure was appropriate for ARX-04.

No change to the price target of $7.00

For an analyst ratings summary and ratings history on AcelRx Pharmaceuticals click here. For more ratings news on AcelRx Pharmaceuticals click here.

Shares of AcelRx Pharmaceuticals closed at $3.80 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment